Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2024 Q2- Text added to 2024 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
New words:
concept, CRR, cutoff, deprioritized, DOR, drew, fatigue, Food, free, hypotension, led, median, Notably, percent, pyrexia, ramp, rare, RECIST, regimen, threshold, undergone, unique
Removed:
adjuvant, antigen, BCC, breast, chemotherapy, chondrosarcoma, clear, compelling, CT, demonstrated, demonstration, durability, epithelioid, expressed, extension, funded, insensitive, leiomyosarcoma, manufactured, MOA, osteosarcoma, partial, purpose, radiation, recurrent, replication, secondary, snapshot, SOC, soft, tissue, uninjected, utility
Valuein 2024 Q2 filing- Value in 2024 Q3 filing
Original filings
Filing view